Print Page  Close Window

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/15/17Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference
EMERYVILLE, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will conduct investor meetings at the RBC Capital Markets Healthcare Conference, taking place February 22-23, 2017, in New York, NY. About Zogenix Zogenix, Inc. (Nasdaq:ZGNX... 
Printer Friendly Version
02/13/17Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada EMERYVILLE, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced the initiation of the clinical efficacy portion of Study 1504 for ZX008 in patients with Dravet syndrome.  Study 1504 is a... 
Printer Friendly Version
02/08/17Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
EMERYVILLE, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Leerink Partners 6th Annual Global Healthcare Conference in New York on February 15, 2017. Leerink Partners 6th Annual Global Healthcare Conference -- Zogenix Presentation Details Date: Wedn... 
Printer Friendly Version
01/30/17Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
Issued Patent is First Covering Company’s Treatment of Seizures Associated with Dravet Syndrome Using Fenfluramine as an Adjunctive Therapy EMERYVILLE, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today the recent issuance of U.S. Patent No. 9,549,909 from the U.S. Patent & Trademark Office.  The patent, entitled “Method for the Treatmen... 
Printer Friendly Version
01/05/17Zogenix Announces CFO Transition
Ann D. Rhoads to Depart Company Following Transition Period; Biopharmaceutical Industry Veteran Michael P. Smith Appointed New CFO EMERYVILLE, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that due to the Company’s ongoing relocation of all corporate functions, including finance, from San Diego, CA, to Emeryville, CA, Ann D. Rhoads, Exe... 
Printer Friendly Version